References
- Kowalski K, Jeznach A, Tuokko HA. Stages of driving behavior change within the Transtheoretical Model (TM). J Safety Res 2014; 50: 17–25.
- Gutierrez-Abejón E, Herrera-Gómez F, Criado-Espegel P, Alvarez FJ. Use of driving-impairing medicines by a Spanish population: a population-based registry study. BMJ Open 2017; 7(11): e017618.
- Alonso F, Esteban C, Sanmartín J, Useche SA. Consistency between the subjective perception of feeling indisposed, the decision to drive and driving performance. Sci J Public Health 2016; 4(6): 482–8.
- Driver and Vehicle Licensing Agency. Assessing Fitness to Drive–a Guide for Medical Professionals. London: Department for transport; 2016.
- Haghi A, Ketabi D, Ghanbari M, Rajabi, H. Assessment of human errors in driving accidents; analysis of the causes based on aberrant behaviors. Life Sci J 2014; 11(9): 414–20.
- Del Río MC, Alvarez FJ. Medication and fitness to drive. Pharmacoepidemiol Drug Saf. 2003; 12(5): 389–94.
- Sigona N, Williams KG. Driving under the influence, public policy, and pharmacy practice. J Pharm Pract 2015; 28(1): 119–23.
- Brady JE, Li G. Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999–2010. Am J Epidemiol 2014; 179(6): 692–9.
- Rudisill TM, Zhu M, Kelley GA, Pilkerton C, Rudisill BR. Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review. Accid Anal Prev 2016; 96: 255–70.
- Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004; 23: 319–44.
- Duquet N. Drugs and driving [Conduite et médicaments]. J Pharm Belg 2013; (2): 4–11.
- Verster JC, Roth T. Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality. Psychopharmacology 2012; 219(3): 775–81.
- Hetland A, Carr DB. Medications and impaired driving. Ann Pharmacother 2014; 48(4): 494–506.
- Kelley-Baker T, Waehrer G, Pollini RA. Prevalence of Self-Reported Prescription Drug Use in a National Sample of U.S. Drivers. J Stud Alcohol Drugs 2017; 78(1): 30–8.
- Walsh JM, Verstraete AG, Huestis MA, Mørland J. Guidelines for research on drugged driving. Addiction 2008; 103(8): 1258–68.
- Ramaekers JG. Drugs and Driving Research in Medicinal Drug Development. Trends Pharmacol Sci 2017; 38(4): 319–21.
- Albrecht M. The “Driving under the Influence of Drugs, Alcohol and Medicines”(DRUID) project of the European Commission. Dtsch Med Wochenschr 2008; 133 Suppl 2: S45–6.
- European Monitoring Centre for Drugs and Drug Addiction. Driving Under the Influence of Drugs, Alcohol and Medicines in Europe — findings from the DRUID project. Luxembourg: Publications Office of the European Union; 2012.
- Act about road traffic safety. Official Gazette of Republic of Serbia. 2018; 24.
- Newnam S, Greenslade J, Newton C, Watson B. Safety in occupational driving: Development of a driver behaviour scale for the workplace context. Appl Psychol-Int Rev 2011; 60: 576–99.
- Davey J, Wishart D, Freeman J, Watson B. An application of the driver behaviour questionnaire in an Australian organisational fleet setting. Transport Res Part F Traffic Psychol Behav 2007; 10(1): 11–21.
- Poulter DR, Chapman P, Bibby PA, Clarke DD, Crundall D. An application of the theory of planned behaviour to truck driving behaviour and compliance with regulations. Accid Anal Prev 2008; 40(6): 2058–64.
- Vearrier D, Vearrier L, McKeever R, Okaneku J, LaSala G, Goldberger D, McCloskey K. Issues in driving impairment. Dis Mon 2016; 62(4): 72–116.
- Girotto E, Mesas AE, de Andrade SM, Birolim MM. Psychoactive substance use by truck drivers: a systematic review. Occup Environ Med 2014; 71(1): 71–6.
- Girotto E, Guidoni CM, González AD, Mesas AE, Andrade SM. Continued use of drugs and working conditions among truck drivers. Cien Saude Colet 2016; 21(12): 3769–76.
- Okamura K, Fujita G, Kihira M, Kosuge R. Patterns of use, knowledge, and perceived effects of sedating medication on driving: a questionnaire survey of Japanese drivers who use sedating medication. Transport Res Part F Traffic Psychol Behav 2018; 54: 276–89.
- Williamson A. Predictors of psychostimulant use by long-distance truck drivers. Am J Epidemiol 2007; 166(11): 1320–6.
- Mir MU, Razzak JA, Ahmad K. Commercial vehicles and road safety in Pakistan: exploring high-risk attributes among drivers and vehicles. Int J Inj Contr Saf Promot 2013; 20(4): 331–8.
- Couper FJ, Pemberton M, Jarvis A, Hughes M, Logan BK. Prevalence of drug use in commercial tractor-trailer drivers. J Forensic Sci 2002; 47(3): 562–7.
- Kagashe G, Seleman K. Knowledge, attitude and practice of commercial drivers in Dar es Salaam with regard to medicines that impair driving. Trop J Pharm Res 2009; 8(4): 297–302.
- Monteiro SP, van Dijk L, Verstraete AG, Alvarez FJ, Heissing M, de Gier JJ. Predictor for patient knowledge and reported behaviors regarding driving under the influence of medicines: a multi-country survey. BMC Public Health 2012; 12: 59.
- MacLennan PA, Owsley C, Rue LW, McGwin G. Older adults’ knowledge about medications that can impact driving Washington DC, United States of America: AAA foundation for traffic safety; 2009.
- Veldhuijzen DS, Van Wijck AJM, Verster JC, et al. The impact of patients’ psychotropic drug knowledge and warning labels on the decision whether to drive a car or not. Traffic Inj Prev 2006; 7(4): 360–4.
- DeVellis RF. Scale Development: Theory and Applications (Applied Social Research Methods), 3rd edition. London: SAGE publications; 2011.
- Ravera S, Monteiro SP, de Gier JJ, van der Linden T, Gómez-Talegón T, Alvarez FJ; DRUID Project WP4 Partners. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol 2012; 74(6): 920–31.
- Fierro I, Gómez-Talegón T, Alvarez FJ. The Spanish pictogram on medicines and driving: The population’s comprehension of and attitudes towards its use on medication packaging. Accid Anal Prev 2013; 50: 1056–61.
- Monteiro S, Huiskes R, van Dijk L, van Weert J, de Gier J. How effective are pictograms in communicating risk about driving-impairing medicines? Traffic Inj Prev 2013; 14(3): 299–308.
- Emich B, van Dijk L, Monteiro SP, de Gier JJ. A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines. Int J Clin Pharm 2014; 36(6): 1152–9.
- Smyth T, Sheehan M, Siskind V. Hospital outpatients’ responses to taking medications with driving warnings. Traff Inj Prev 2013; 14(1): 18–25.
- Brooke BT, Southward RD. An audit on advice on fitness to drive during accident and Emergency Department attendance. Emerg Med J 2006; 23(2): 103–4.
- Laaksonen R, Duggan C, Bates I. Desire for information about drugs: relationships with patients’ characteristics and adverse effects. Pharm World Sci 2002; 24(5): 205–10.
- Legrand SA, Boets S, Meesmann U, Verstraete AG. Medicines and driving: evaluation of training and software support for patient counselling by pharmacists. Int J Clin Pharm 2012; 34(4): 633–43.
- Elder RW, Shults RA, Sleet DA, Nichols JL, Thompson RS, Rajab W; Task Force on Community Preventive Services. Effectiveness of mass media campaigns for reducing drinking and driving and alcohol-involved crashes: a systematic review. Am J Prev Med 2004; 27(1): 57–65.
- Elayeh E, Bulatova N, Basheti I, Abu Farha R, Al-Rawi N, Abu Snaineh A, Alahwal I. The use and safety of medications known to affect driving in Jordan: A cross-sectional study. Traffic Inj Prev 2016; 17(3): 238–44.
- Labat L, Fontaine B, Delzenne C, Doublet A, Marek MC, Tellier D, Tonneau M, Lhermitte M, Frimat P. Prevalence of psychoactive substances in truck drivers in the Nord-Pas-de-Calais region (France). Forensic Sci Int 2008; 174(2–3): 90–4.
- Herrera-Gómez F, Gutierrez-Abejón E, Criado-Espegel P, Álvarez FJ. The Problem of Benzodiazepine Use and Its Extent in the Driver Population: A Population-Based Registry Study. Front Pharmacol 2018; 9: 408.
- Drummer OH, Yap S. The involvement of prescribed drugs in road trauma. Forensic Sci Int 2016; 265: 17–21.